Table 1.
Baseline characteristics
| Baseline characteristics | n = 9444 |
|---|---|
| Age (years), mean (±SD) | 69.1 (±11.4) |
| Female sex, n (%) | 3776 (40.0%) |
| BMI (kg/m2), mean (±SD) | 28.3 (±5.1) |
| eGFR (mL/min/1.73 m2), mean (±SD) | 69.4 (±21.2) |
| LA diameter (mm), mean (±SD) | 45.4 (±8.2) |
| LV ejection fraction (%),mean (±SD) | 53.7 (±13.0) |
| Left ventricular hypertrophy, n (%) | 2181 (27.5%) |
| AF classification, n (%) | |
| ȃFirst-detected | 1452 (15.6%) |
| ȃParoxysmal | 2468 (26.6%) |
| ȃPersistent | 1850 (19.9%) |
| ȃLong-standing persistent | 420 (4.5%) |
| ȃPermanent | 3099 (33.4%) |
| EHRA classification, n (%) | |
| ȃI | 4283 (45.4%) |
| ȃII | 3373 (35.7%) |
| ȃIII | 1592 (16.9%) |
| ȃIV | 196 (2.1%) |
| Comorbidities, n (%) | |
| ȃCardiomyopathy | 1367 (14.5%) |
| ȃCongenital heart disease | 103 (1.1%) |
| ȃCOPD | 815 (8.7%) |
| ȃCoronary artery disease | 2551 (28.3%) |
| ȃDiabetes mellitus | 2142 (22.7%) |
| ȃHeart failure | 3569 (37.8%) |
| ȃHypertension | 5843 (61.9%) |
| ȃLiver disease | 236 (2.5%) |
| ȃPeripheral vascular disease | 748 (7.9%) |
| ȃPrevious haemorrhagic event | 501 (5.3%) |
| ȃPrevious thromboembolic event | 1093 (11.6%) |
| ȃPrevious ischaemic stroke | 572 (6.1%) |
| ȃSleep apnoea | 440 (4.8%) |
| ȃHyperthyroidism | 168 (1.8%) |
| ȃHypothyroidism | 511 (5.5%) |
| ȃValvular heart disease | 4629 (49.7%) |
| Prior catheter AF ablation, n (%) | 457 (6.0%) |
| CHA2DS2-VASc score, mean (±SD) | 3.1 (±1.8) |
| HAS-BLED score, mean (±SD) | 1.6 (±1.1) |
AF, atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; EHRA, European Heart Rhythm Association; LA, left atrium; LV, left ventricle; SD, standard deviation.